Dimerix (DXB) Investor presentation summary

Strategic focus and pipeline

• Developing therapies for kidney diseases with significant unmet clinical needs, focusing on FSGS and acute kidney injury.

• DMX-200 targets FSGS, a rare disease causing irreversible kidney damage, and has completed Phase 3 recruitment.

• DMX-652 is a first-in-class asset for acute kidney injury, ready for Phase 2 trials, with FDA clearance and manufacturing completed.

• Both assets leverage shared renal expertise, regulatory infrastructure, and commercial relationships.

Clinical development and trial progress

• DMX-200 Phase 3 ACTION3 trial fully recruited with 333 adult patients across global sites; interim analysis showed strong statistical power for primary endpoint.

• Open label extension study for DMX-200 has 92% of eligible patients enrolled.

• DMX-652 Phase 2 trial will enroll 160 high-risk cardiac surgery patients to assess AKI incidence and safety.

• Key value inflection points include Phase 3 readout for DMX-200 and Phase 2 milestones for DMX-652.

Commercial partnerships and financials

• Five commercial licensing partners for DMX-200 across major global markets, with deals valued up to AU$1.9 billion in upfront, milestone payments, and royalties.

• Upfront payments exceed AU$80 million, with diversified revenue streams and risk sharing.

• Royalties range from 10% to 30% depending on territory and partner.

• Market capitalization at AU$150 million, cash balance of AU$16.2 million as of June 2026, and additional available facilities.